How should tiratricol (triiodothyroacetic acid) be dosed, monitored, and what are its contraindications and alternatives?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tiratricol (Triiodothyroacetic Acid/TRIAC)

Primary Indication and Approval

Tiratricol is specifically approved for treating peripheral thyrotoxicosis in patients with MCT8 deficiency (Allan-Herndon-Dudley Syndrome), not for general hyperthyroidism management. 1 This represents its first and only regulatory approval as of February 2025 in the European Union.

Dosing

For MCT8 Deficiency (Approved Indication)

  • Starting dose: 350 μg once daily (available as dispersible tablets)
  • Dose escalation: Increase by 350 μg increments progressively
  • Target dose: Mean effective dose is 38.3 μg/kg body weight (range 6.4-84.3 μg/kg) 2
  • Goal: Achieve serum total T3 concentrations within 1.4-2.5 nmol/L
  • Titration frequency: Adjust based on T3 levels until target range achieved

The dose-dependent nature of TRIAC requires individualized titration, as demonstrated in the pivotal trial where patients needed widely varying doses to normalize T3 levels 2.

For Thyroid Hormone Resistance β (Off-Label, Investigational)

  • Typical range: 500-3000 μg daily in divided doses
  • Pediatric experience: Up to 3.0 mg/day has been used safely in children 3
  • Important caveat: TRIAC has a short half-life and rapid clearance, necessitating multiple daily doses for sustained effect 3

Monitoring

Biochemical Parameters

Primary monitoring targets:

  • Serum total T3: Target 1.4-2.5 nmol/L for MCT8 deficiency 2
  • Free T4 and total T4: Should decrease from baseline
  • TSH: Expected to decrease (mean reduction 1.89 mU/L in MCT8 patients) 2
  • Reverse T3: Monitor for reduction

Monitoring frequency:

  • During dose titration: Every 4-6 weeks (extrapolated from standard hyperthyroidism guidelines 4)
  • Once stable: Every 3-6 months

Clinical Parameters

Monitor for:

  • Cardiovascular: Heart rate, blood pressure (TRIAC appears to spare cardiac effects compared to T3) 5, 6
  • Growth parameters: Weight, height in pediatric patients
  • Neurological symptoms: ADHD symptoms may improve in RTHβ patients 3
  • Body temperature: Should remain stable (no hyperthermia expected) 5

Contraindications

Absolute Contraindications

Based on FDA labeling for thyroid hormone analogs 7:

  • Hypersensitivity to tiratricol or any component
  • Pregnancy (thyroid hormone analogs cross placenta)
  • Breastfeeding (excreted in breast milk)

Relative Contraindications/Cautions

  • Coexisting Graves' disease: One patient in the MCT8 trial developed Graves' disease during treatment, requiring discontinuation 2
  • Severe pre-existing cardiac disease: Though TRIAC appears cardioprotective compared to T3, caution is warranted
  • Active infections: Serious infections occurred in 39% of MCT8 patients, though unrelated to treatment 2

Adverse Effects

Common (from MCT8 trial) 2

  • Treatment-related (13% of patients):
    • Transiently increased perspiration
    • Irritability

Serious Adverse Events

  • 26 serious adverse events in 18/46 patients (39%) - mostly hospital admissions for infections, considered unrelated to TRIAC 2
  • One death from pulmonary sepsis/multi-organ failure (unrelated to treatment)
  • Cardiovascular effects: Nervousness, cardiac arrhythmia, or tachycardia reported in 4 patients when used off-label at 500 μg daily 8

Alternatives and Context

For MCT8 Deficiency

No effective alternatives exist. Standard thyroid hormone therapy (levothyroxine or T3) cannot enter cells without MCT8 and therefore fails to treat this condition. TRIAC's unique ability to enter cells independent of MCT8 makes it the only viable option 2, 1.

For Thyroid Hormone Resistance β

Standard approach remains observation or symptomatic treatment 4. TRIAC is investigational for this indication:

  • Shows promise in reducing hyperthyroid symptoms and normalizing T4/T3 without raising TSH 6
  • Reduces resting energy expenditure and symptom scores 6
  • Critical limitation: Historical data shows TRIAC has parallel effects on pituitary and peripheral tissues, offering no advantage over supraphysiologic levothyroxine for TSH suppression in most contexts 9

For General Hyperthyroidism

TRIAC is NOT indicated. Standard treatments remain 4:

  1. Methimazole (first-line antithyroid drug)
  2. Radioactive iodine (RAI therapy)
  3. Thyroidectomy

Key Clinical Pitfalls

  1. Do not use TRIAC for routine hyperthyroidism management - it lacks approval and evidence for this indication
  2. Recognize the short half-life - requires careful dose titration and potentially multiple daily doses for sustained effect 3
  3. Monitor for autoimmune thyroid disease development - one case report documents loss of TRIAC efficacy when Graves' disease developed concurrently 10
  4. Pregnancy testing mandatory - exclude pregnancy within 48 hours before initiating treatment (extrapolated from RAI guidelines 11)
  5. Infection vigilance - MCT8 patients have high infection rates; maintain high clinical suspicion 2

References

Research

Tiratricol: First Approval.

Drugs, 2025

Guideline

hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the american thyroid association and american association of clinical endocrinologists.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.